What retatrutide is
Retatrutide is a once-weekly peptide that activates three receptors at once: GIP, GLP-1 and glucagon. The first two are shared with tirzepatide. The third — glucagon receptor agonism — is the addition, and it appears to increase energy expenditure and shift how the liver handles fat.
It is being developed by Eli Lilly. It is investigational, meaning it is still in clinical development and has not been approved by any medicines regulator.
The evidence has moved
For several years retatrutide was a phase 2 story: a single well-publicised trial published in 2023 showing weight reduction of around 24% at 48 weeks. That is no longer the position.
Phase 3 results have now reported. TRIUMPH-4 read out in December 2025 with roughly 28.7% mean weight reduction at 68 weeks. TRIUMPH-1, a larger general obesity trial of over 2,300 participants, confirmed around 28.3% at 80 weeks, with a prespecified extension reaching approximately 30% at 104 weeks. Further phase 3 trials in diabetes and cardiovascular disease have since reported positive primary endpoints.
The honest summary is that retatrutide works, and works unusually well. That is not the part in dispute.
Regulatory submission is anticipated but has not yet resulted in approval anywhere.
Why "the trials worked" does not mean "the vial is fine"
Retatrutide is not manufactured for sale. There is no licensed product, no legitimate supply chain, and no pharmacy anywhere that can dispense it. Every vial being sold online was produced outside the development programme by an unrelated manufacturer, with no regulatory oversight of what went into it.
This is the specific trap with retatrutide, and it is worse than with most compounds on this site precisely because the trial data is so good. Strong published results create the impression that the substance is understood and therefore safe to obtain. But the results describe material made to clinical standards with verified identity, purity and sterility. That description does not transfer to a vial bought online.
Peptide synthesis at scale is difficult. Truncated sequences, deletion impurities, residual solvents and endotoxin contamination are real manufacturing problems that pharmaceutical quality systems exist to control. An unregulated producer has no obligation to control any of them, and no consequence if they do not.
What the trials also found
Gastrointestinal adverse events dominated the safety picture across the phase 3 programme, with discontinuation rates attributable to them running meaningfully above placebo. Dose escalation schedules in the trials exist specifically to manage this, and were designed by the people running the study rather than derived from forums.
The glucagon component adds considerations the GLP-1 drugs do not have, including effects on heart rate and on hepatic glucose output. These are being characterised properly in the trial programme. They are not characterised at all in unsupervised use.
Approval is not a formality
It is tempting to treat the gap between "positive phase 3" and "approved" as paperwork. It is not. Regulatory review examines the full safety dataset, including rare events that only appear across thousands of participants, manufacturing quality, and long-term follow-up. Drugs with positive phase 3 results have failed at this stage before.
If retatrutide is approved, it will be available through pharmacies with a known formulation, verified content and a prescriber assessing suitability. Everything currently available lacks all three.
Where this leaves you
Retatrutide is likely to become a significant medicine. The evidence supporting it is real, large and now replicated at phase 3. None of that makes an unregulated vial of uncertain content a reasonable proxy for the drug that was tested.